Nycomed CEO Hakån Björklund talks about the sale of his company to its Japanese competitor Takeda. He believes that the two companies are well-matched in strategic terms. Björklund has been CEO (chief executive officer) of Nycomed since 1999.
No, Nycomed is an excellent company and is worth such a large sum of money.
I couldn’t say exactly what my personal contribution to Nycomed’s value has been. I had the privilege of being CEO of the company and over the last few years, together with many talented and energetic colleagues, we’ve been able to put in place an excellent organisation and a growing and sustainable business. I consider myself lucky to have been part of this process.
I will initially stay on as CEO until the deal is completed, which will probably be in September. Until then, Nycomed will remain an independent company. I have committed myself to assisting with the integration of Nycomed into Takeda; however, what my role will be and how this will be done remains to be seen. In any case, it is very important to me to be able to contribute as much as I can in order to ensure that the integration of Nycomed into Takeda is successful.
Sorry, I’m unable to give you any exact figures. But I know that the investors are very proud that their investments have contributed to Nycomed becoming a world-class pharmaceutical company.
As I have already told you, it’s very difficult to put into numbers. The transaction with Takeda involves 9.6 billion euros, part of which has been invested by the owners. The debts accrued by the current owners that will be paid back at the end of the transaction also have to be taken into account.
What I can say is, the reason for the transaction is that Nycomed and Takeda complement each other very well. Takeda has a strong presence in the USA and Japan and Nycomed has a strong presence in Europe and markets in threshold countries. The reason for Takeda acquiring Nycomed therefore has nothing to do with potential synergies. Takeda’s decision to purchase is not principally driven by cost savings. In fact, almost the opposite is true. That said, there are of course areas where the two companies overlap. These overlaps will be evaluated within the next few months and a decision on potential company reorganisation will be made. At present, I am unable to say anything about potential changes in any of Nycomed’s three sites in Konstanz, Singen, Roskilde (DK) or Moscow (RU).
I’m afraid I know very little.
Of course, this is something we will talk about in the coming months. Not just in respect of research activities, but also with regard to administration, sales and marketing. But it is much too early to speculate about any potential outcome.
We have an excellent pipeline and we are very pleased to have several projects in late clinical phases of development. Some products, such as Daxas and Instanyl, have been launched and we have applied for marketing authorisation for Teduglutide and EffRx. Considering the size of Nycomed, these are excellent figures.
Absolutely. My Konstanz colleagues can be truly proud of their achievements.
I don’t know. We have no plans to do so, but speculation about the future doesn’t get us anywhere. The transaction with Bracco was excellent for all parties involved, for us, for Bracco and in particular for the employees who are now part of a company whose product they have been producing for quite some years. I am sure Bracco will be more interested than Nycomed in investing in this area. We only served as contract manufacturers. And I am sure any investment by Bracco is in the interest of the employees.
In the short term, there won’t be any changes. We will continue to produce and sell our products. In the medium to long term, it might be beneficial for our clients. Take Daxas, for example. The acquisition of Nycomed by Takeda will give us much stronger sales channels, which means that we will be able to distribute the product to a much larger number of patients worldwide. And the same of course goes for Takeda products.